Uncovering NINJ1 in SLE: Biomarker potential for renal and hematologic manifestations

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-05-05 DOI:10.1016/j.cca.2025.120347

Muyuan Li , Ke Liu , Meidong Liu , Huali Zhang , Yiying Yang

{"title":"Uncovering NINJ1 in SLE: Biomarker potential for renal and hematologic manifestations","authors":"Muyuan Li , Ke Liu , Meidong Liu , Huali Zhang , Yiying Yang","doi":"10.1016/j.cca.2025.120347","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Systemic lupus erythematosus (SLE) is a complex autoimmune disease, with an unclear etiology. This study investigated the clinical relevance of serum NINJ1 levels in SLE and evaluated its potential as a biomarker.</div></div><div><h3>Methods</h3><div>Serum NINJ1 levels were measured in 99 newly diagnosed SLE patients and 43 healthy controls. Associations with clinical features, inflammatory markers, and autoantibodies were analyzed. ROC curve analysis was performed for diagnostic evaluation.</div></div><div><h3>Results</h3><div>Serum NINJ1 levels were significantly higher in SLE patients (p < 0.0001) and further elevated in those with lupus nephritis (LN) and thrombocytopenia. Positive correlations with proteinuria, CRP, and NLR were found. ROC analysis showed good diagnostic performance (AUC = 0.83).</div></div><div><h3>Conclusion</h3><div>Serum NINJ1 is a promising biomarker for SLE, particularly for identifying LN and thrombocytopenia, and may aid in disease stratification and monitoring.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"574 ","pages":"Article 120347"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002268","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Systemic lupus erythematosus (SLE) is a complex autoimmune disease, with an unclear etiology. This study investigated the clinical relevance of serum NINJ1 levels in SLE and evaluated its potential as a biomarker.

Methods

Serum NINJ1 levels were measured in 99 newly diagnosed SLE patients and 43 healthy controls. Associations with clinical features, inflammatory markers, and autoantibodies were analyzed. ROC curve analysis was performed for diagnostic evaluation.

Results

Serum NINJ1 levels were significantly higher in SLE patients (p < 0.0001) and further elevated in those with lupus nephritis (LN) and thrombocytopenia. Positive correlations with proteinuria, CRP, and NLR were found. ROC analysis showed good diagnostic performance (AUC = 0.83).

Conclusion

Serum NINJ1 is a promising biomarker for SLE, particularly for identifying LN and thrombocytopenia, and may aid in disease stratification and monitoring.

查看原文本刊更多论文

在SLE中发现NINJ1：肾脏和血液学表现的生物标志物潜力

目的系统性红斑狼疮（SLE）是一种病因不明的复杂自身免疫性疾病。本研究探讨了SLE患者血清NINJ1水平的临床相关性，并评估了其作为生物标志物的潜力。方法测定99例SLE新诊断患者和43例健康对照者血清NINJ1水平。分析了与临床特征、炎症标志物和自身抗体的关系。采用ROC曲线分析进行诊断评价。结果SLE患者血清NINJ1水平显著升高(p <；0.0001)，在狼疮性肾炎（LN）和血小板减少症患者中进一步升高。与蛋白尿、CRP和NLR呈正相关。ROC分析显示诊断效果良好（AUC = 0.83）。结论血清NINJ1是一种很有前景的SLE生物标志物，特别是在识别LN和血小板减少症方面，可能有助于疾病分层和监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.